The outlook of companies tied to iconic drugs like Viagra presents a challenging investment picture. While the initial rise of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the loss of exclusivity in key markets has introduced significant volatility. Investors are now assessing the consequences of lower-cost a